Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document

Casiraghi, 2011, A 10-year single-center experience on 708 lung metastasectomies: the evidence of the “international registry of lung metastases”, J Thorac Oncol, 6, 1373, 10.1097/JTO.0b013e3182208e58 Fong, 1999, Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases, Ann Surg, 230, 309, 10.1097/00000658-199909000-00004 Miller, 2007, Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases, J Am Coll Surg, 205, 231, 10.1016/j.jamcollsurg.2007.04.039 Tree, 2013, Stereotactic body radiotherapy for oligometastases, Lancet Oncol, 14, e28, 10.1016/S1470-2045(12)70510-7 Dingemans, 2019, Definition of synchronous oligo-metastatic non-small cell lung cancer – a consensus report, J Thorac Oncol, 10.1016/j.jtho.2019.07.025 Hellman, 1995, Oligometastases, J Clin Oncol, 13, 8, 10.1200/JCO.1995.13.1.8 Lewis D, Gardner E. “Do the trials”: Caution urged in ASTRO Presidential Symposium on routine use of SABR as curative in metastatic cancer. 2019. Lewis, 2017, Definitive stereotactic body radiotherapy (SBRT) for extracranial oligometastases: an international survey of >1000 radiation oncologists, Am J Clin Oncol, 40, 418, 10.1097/COC.0000000000000169 Gomez, 2019, Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, Phase II, randomized study, J Clin Oncol, 37, 1558, 10.1200/JCO.19.00201 Iyengar, 2018, Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial, JAMA Oncol, 4, 10.1001/jamaoncol.2017.3501 Ost, 2018, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial, J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853 Palma, 2019, Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial, Lancet, 393, 2051, 10.1016/S0140-6736(18)32487-5 Ruers, 2017, Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial, J Natl Cancer Inst, 109, 10.1093/jnci/djx015 Giaj-Levra, 2019, Defining synchronous oligometastatic non-small cell lung cancer: a systematic review, J Thorac Oncol, 10.1016/j.jtho.2019.05.037 Schanne, 2019, Evolution of treatment strategies for oligometastatic NSCLC patients – A systematic review of the literature, Cancer Treat Rev, 80, 10.1016/j.ctrv.2019.101892 Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med, 6, 10.1371/journal.pmed.1000097 Nguyen, 2018, Optimal imaging surveillance after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer: Findings of an International Delphi Consensus Study, Pract Radiat Oncol, 8, e71, 10.1016/j.prro.2017.10.008 Barata, 2018, Effect of switching systemic treatment after stereotactic radiosurgery for oligoprogressive, metastatic renal cell carcinoma, Clin Genitourin Cancer, 16, 10.1016/j.clgc.2018.07.018 Bowden, 2019, Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: interim outcomes of a prospective clinical trial, Int J Cancer De Bleser, 2019, Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy, Eur Urol, 10.1016/j.eururo.2019.07.009 De Rose, 2016, Clinical outcome of stereotactic ablative body radiotherapy for lung metastatic lesions in non-small cell lung cancer oligometastatic patients, Clin Oncol (R Coll Radiol), 28, 13, 10.1016/j.clon.2015.08.011 Decaestecker, 2014, Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence, Radiat Oncol, 9, 135, 10.1186/1748-717X-9-135 Dell'Acqua, 2019, Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions, Clin Exp Metastasis, 36, 331, 10.1007/s10585-019-09976-z Didolkar, 1977, Metastatic carcinomas from occult primary tumors. A study of 254 patients, Ann Surg, 186, 625, 10.1097/00000658-197711000-00014 Fleckenstein, 2016, Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer, BMC Cancer, 16, 348, 10.1186/s12885-016-2379-x Franzese, 2018, Liver metastases from colorectal cancer: propensity score-based comparison of stereotactic body radiation therapy vs. microwave ablation, J Cancer Res Clin Oncol, 144, 1777, 10.1007/s00432-018-2692-7 Franzese, 2019, Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy, Radiother Oncol, 133, 220, 10.1016/j.radonc.2018.10.024 Franzese, 2019, Role of stereotactic body radiation therapy for the management of oligometastatic renal cell carcinoma, J Urol, 201, 70, 10.1016/j.juro.2018.08.049 Franzese, 2018, The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer, Cancer Med, 7, 4379, 10.1002/cam4.1707 Gerum, 2018, Stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma and oligometastatic liver disease, Radiat Oncol, 13, 100, 10.1186/s13014-018-1048-4 Gomez, 2016, Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study, Lancet Oncol, 17, 1672, 10.1016/S1470-2045(16)30532-0 Horner-Rieber, 2019, Long-term follow-up and patterns of recurrence of patients with oligometastatic NSCLC treated with pulmonary SBRT, Clin Lung Cancer, 10.1016/j.cllc.2019.06.024 Hoyer, 2006, Phase II study on stereotactic body radiotherapy of colorectal metastases, Acta Oncol, 45, 823, 10.1080/02841860600904854 Hu, 2019, Efficacy of local consolidative therapy for oligometastatic lung adenocarcinoma patients harboring epidermal growth factor receptor mutations, Clin Lung Cancer, 20, e81, 10.1016/j.cllc.2018.09.010 Jingu, 2017, Dose escalation improves outcome in stereotactic body radiotherapy for pulmonary oligometastases from colorectal cancer, Anticancer Res, 37, 2709, 10.21873/anticanres.11621 Kinj, 2017, Radiosensitivity of colon and rectal lung oligometastasis treated with stereotactic ablative radiotherapy, Clin Colorectal Cancer, 16, e211, 10.1016/j.clcc.2016.08.003 Kneebone, 2018, Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission tomography, Eur Urol Oncol, 1, 531, 10.1016/j.euo.2018.04.017 Kwint, 2017, Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases, Lung Cancer, 112, 134, 10.1016/j.lungcan.2017.08.006 Lazzari, 2018, Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday, Int J Radiat Oncol Biol Phys, 101, 650, 10.1016/j.ijrobp.2018.03.058 Lepinoy, 2019, Salvage extended field or involved field nodal irradiation in (18)F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer, Eur J Nucl Med Mol Imaging, 46, 40, 10.1007/s00259-018-4159-0 Merino Lara, 2018, Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: delaying the need to start or change systemic therapy?, Lung Cancer, 124, 219, 10.1016/j.lungcan.2018.08.005 Meyer, 2018, Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: a study of the Getug group, Eur J Cancer, 98, 38, 10.1016/j.ejca.2018.04.008 Mihai, 2017, Patients with colorectal lung oligometastases (L-OMD) treated by dose adapted SABR at diagnosis of oligometastatic disease have better outcomes than patients previously treated for their metastatic disease, J Radiosurg SBRT, 5, 43 Ost, 2016, Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis, Eur Urol, 69, 9, 10.1016/j.eururo.2015.07.004 Ouyang, 2019, Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer, Cancer Med, 8, 4605, 10.1002/cam4.2366 Park, 2015, Stereotactic body radiotherapy for recurrent or oligometastatic uterine cervix cancer: a Cooperative Study of the Korean Radiation Oncology Group (KROG 14–11), Anticancer Res, 35, 5103 Petty, 2018, Long-term outcomes of a phase 2 trial of chemotherapy with consolidative radiation therapy for oligometastatic non-small cell lung cancer, Int J Radiat Oncol Biol Phys, 102, 527, 10.1016/j.ijrobp.2018.06.400 Santini, 2017, Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis, Oncotarget, 8, 100708, 10.18632/oncotarget.20022 Schick, 2013, Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases, Acta Oncol, 52, 1622, 10.3109/0284186X.2013.764010 Tran, 2018, Oligorecurrent nodal prostate cancer: long-term results of an elective nodal irradiation approach, Am J Clin Oncol, 41, 960, 10.1097/COC.0000000000000419 Trovo, 2018, Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial, Radiother Oncol, 126, 177, 10.1016/j.radonc.2017.08.032 Andratschke, 2018, The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases, BMC Cancer, 18, 283, 10.1186/s12885-018-4191-2 Aoki, 2016, Stereotactic body radiotherapy for lung metastases as oligo-recurrence: a single institutional study, J Radiat Res, 57, 55, 10.1093/jrr/rrv063 Berber, 2013, Multicentre results of stereotactic body radiotherapy for secondary liver tumours, HPB (Oxford), 15, 851, 10.1111/hpb.12044 Dohopolski, 2018, Stereotactic body radiation therapy for pulmonary oligometastases arising from non-lung primaries in patients without extrapulmonary disease, Cureus, 10 Fleming, 2017, Palliative efficacy and local control of conventional radiotherapy for lung metastases, Ann Palliat Med, 6, S21, 10.21037/apm.2017.03.08 Franceschini, 2017, Role of stereotactic body radiation therapy for lung metastases from radio-resistant primary tumours, J Cancer Res Clin Oncol, 143, 1293, 10.1007/s00432-017-2373-y Franzese, 2016, Role of stereotactic body radiation therapy with volumetric-modulated arcs and high-intensity photon beams for the treatment of abdomino-pelvic lymph-node metastases, Cancer Invest, 34, 348, 10.1080/07357907.2016.1197235 Frelinghuysen, 2018, Acute toxicity of the bowel after stereotactic robotic radiotherapy for abdominopelvic oligometastases, Acta Oncol, 57, 480, 10.1080/0284186X.2017.1378432 Goodman, 2016, Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases, Pract Radiat Oncol, 6, 86, 10.1016/j.prro.2015.10.011 Helou, 2017, Stereotactic ablative radiation therapy for pulmonary metastases: histology, dose, and indication matter, Int J Radiat Oncol Biol Phys, 98, 419, 10.1016/j.ijrobp.2017.02.093 Jereczek-Fossa, 2014, Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer, Am J Clin Oncol, 37, 227, 10.1097/COC.0b013e3182610878 Klement, 2017, Stereotactic body radiotherapy for oligo-metastatic liver disease – Influence of pre-treatment chemotherapy and histology on local tumor control, Radiother Oncol, 123, 227, 10.1016/j.radonc.2017.01.013 Klement, 2018, Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy, Radiother Oncol, 127, 246, 10.1016/j.radonc.2018.02.016 Lancia, 2017, Oligometastatic cancer: stereotactic ablative radiotherapy for patients affected by isolated body metastasis, Acta Oncol, 56, 1621, 10.1080/0284186X.2017.1346383 Loi, 2018, Locoregional control and survival after lymph node SBRT in oligometastatic disease, Clin Exp Metastasis, 35, 625, 10.1007/s10585-018-9922-x Mazzola, 2018, Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study, Med Oncol, 35, 121, 10.1007/s12032-018-1190-8 Navarria, 2014, Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments, Radiat Oncol, 9, 91, 10.1186/1748-717X-9-91 Oh, 2012, Potentially curative stereotactic body radiation therapy (SBRT) for single or oligometastasis to the lung, Acta Oncol, 51, 596, 10.3109/0284186X.2012.681698 Osti, 2018, 30 Gy single dose stereotactic body radiation therapy (SBRT): report on outcome in a large series of patients with lung oligometastatic disease, Lung Cancer, 122, 165, 10.1016/j.lungcan.2018.06.018 Osti, 2013, Clinical outcomes of single dose stereotactic radiotherapy for lung metastases, Clin Lung Cancer, 14, 699, 10.1016/j.cllc.2013.06.006 Owen, 2014, Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases, Pract Radiat Oncol, 4, e143, 10.1016/j.prro.2013.05.006 Rieber, 2016, Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group “stereotactic radiotherapy”, Lung Cancer, 97, 51, 10.1016/j.lungcan.2016.04.012 Sharma, 2019, Survival and prognostic factors of pulmonary oligometastases treated with stereotactic body radiotherapy, Acta Oncol, 58, 74, 10.1080/0284186X.2018.1521986 Siva, 2015, Comparison of single-fraction and multi-fraction stereotactic radiotherapy for patients with 18f-fluorodeoxyglucose positron emission tomography-staged pulmonary oligometastases, Clin Oncol (R Coll Radiol), 27, 353, 10.1016/j.clon.2015.01.004 Thibault, 2014, Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience, Clin Oncol (R Coll Radiol), 26, 713, 10.1016/j.clon.2014.06.018 Wang, 2016, Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes, Oncotarget, 7, 18135, 10.18632/oncotarget.7636 Yamashita, 2016, Lung stereotactic radiotherapy for oligometastases: comparison of oligo-recurrence and sync-oligometastases, Jpn J Clin Oncol, 46, 687, 10.1093/jjco/hyw047 Dhondt, 2018, Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time, World J Urol Lussier, 2012, Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs, PLoS ONE, 7, 10.1371/journal.pone.0050141 Lussier, 2011, MicroRNA expression characterizes oligometastasis(es), PLoS ONE, 6, 10.1371/journal.pone.0028650 Pitroda, 2018, Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis, Nat Commun, 9, 1793, 10.1038/s41467-018-04278-6 Pembroke, 2018, Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression, Radiother Oncol, 127, 493, 10.1016/j.radonc.2018.04.022 Aujla, 2019, Hypofractionated stereotactic radiotherapy for non-breast or prostate cancer oligometastases: a tail of survival beyond 10 years, Front Oncol, 9, 111, 10.3389/fonc.2019.00111 Hoyer, 2005, Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma, Radiother Oncol, 76, 48, 10.1016/j.radonc.2004.12.022 Fode, 2015, Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases, Radiother Oncol, 114, 155, 10.1016/j.radonc.2014.12.003 Sutera, 2019, Initial results of a multicenter phase 2 trial of stereotactic ablative radiation therapy for oligometastatic cancer, Int J Radiat Oncol Biol Phys, 103, 116, 10.1016/j.ijrobp.2018.08.027 Laurie, 2019, Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer, Curr Oncol, 26, e81, 10.3747/co.26.4116 Niibe, 2010, Oligometastases and oligo-recurrence: the new era of cancer therapy, Jpn J Clin Oncol, 40, 107, 10.1093/jjco/hyp167 Palma, 2014, The oligometastatic state – separating truth from wishful thinking, Nat Rev Clin Oncol, 11, 549, 10.1038/nrclinonc.2014.96 Reyes, 2015, The biology and treatment of oligometastatic cancer, Oncotarget, 6, 8491, 10.18632/oncotarget.3455 Triggiani, 2017, Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study, Br J Cancer, 116, 1520, 10.1038/bjc.2017.103 Guckenberger, 2020, Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation, Lancet Oncol, 21, e18, 10.1016/S1470-2045(19)30718-1 Agency EM. Guideline on the evaluation of anticancer medicinal products in man. 2017 FDA. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics Guidance for Industry. 2018. Lievens, 2019, Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective, Lancet Oncol, 20, e112, 10.1016/S1470-2045(18)30917-3 Erler, 2018, Local control and fracture risk following stereotactic body radiation therapy for non-spine bone metastases, Radiother Oncol, 127, 304, 10.1016/j.radonc.2018.03.030 Napieralska, 2016, CyberKnife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases, Neoplasma, 63, 304 Chang, 2017, Stereotactic ablative body radiotherapy for the treatment of spinal oligometastases, Clin Oncol (R Coll Radiol), 29, e119, 10.1016/j.clon.2017.02.004 Seo, 2015, Stereotactic body radiotherapy for oligometastases confined to the para-aortic region: clinical outcomes and the significance of radiotherapy field and dose, Cancer Invest, 33, 180, 10.3109/07357907.2015.1019678 deSouza, 2018, Strategies and technical challenges for imaging oligometastatic disease: recommendations from the European Organisation for Research and Treatment of Cancer imaging group, Eur J Cancer, 91, 153, 10.1016/j.ejca.2017.12.012 Al-Shafa, 2019, A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic cancers: where will the evidence lead?, Front Oncol, 9, 543, 10.3389/fonc.2019.00543 Lievens, 2017, Access to innovative radiotherapy: how to make it happen from an economic perspective?, Acta Oncol, 56, 1353, 10.1080/0284186X.2017.1348622 Bhattacharya, 2015, Stereotactic body radiotherapy (SBRT) in the management of extracranial oligometastatic (OM) disease, Br J Radiol., 88, 10.1259/bjr.20140712 Van den Begin, 2019, The METABANK score: A clinical tool to predict survival after stereotactic radiotherapy for oligometastatic disease, Radiother Oncol., 133, 113, 10.1016/j.radonc.2019.01.001 Lancia, 2019, Oligometastatic cancer in elderly patients: the “blitzkrieg” radiotherapy approach, Aging Clin Exp Res., 31, 109, 10.1007/s40520-018-0937-6 Milano, 2011, Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study, Int J Radiat Oncol Biol Phys., 83, 878, 10.1016/j.ijrobp.2011.08.036 Deodato, 2019, Dose escalation in extracranial stereotactic ablative radiotherapy (DESTROY-1): A multi-arm Phase I trial, Br J Radiol., 91 Greco, 2011, Predictors of local control aftersingle-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases, Int J Radiat Oncol Biol Phys., 79, 1151, 10.1016/j.ijrobp.2009.12.038 Wong, 2016, Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT), Cancer., 122, 2242, 10.1002/cncr.30058 de Vin, 2014, Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival, Ann Oncol., 25, 467, 10.1093/annonc/mdt537 Binkley, 2015, Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy, Int J Radiat Oncol Biol Phys., 92, 1044, 10.1016/j.ijrobp.2015.04.004 Erler, 2018, Local control and fracture risk following stereotactic body radiation therapy for non-spine bone metastases, Radiother Oncol., 127, 304, 10.1016/j.radonc.2018.03.030 Muldermans, 2016, Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer, Int J Radiat Oncol Biol Phys., 95, 696, 10.1016/j.ijrobp.2016.01.032 Napieralska, 2016, Cyberknife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases, Neoplasma, 63, 304 Franceschini, 2019, Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy, Int J Radiat Oncol Biol Phys., 104, 111, 10.1016/j.ijrobp.2018.12.049 Kang, 2010, Oligometastases confined one organ from colorectal cancer treated by SBRT, Clin Exp Metastasis., 27, 273, 10.1007/s10585-010-9325-0